Pharma Mar Hits $10 Million Milestone with Janssen
Company Announcements

Pharma Mar Hits $10 Million Milestone with Janssen

Pharma Mar SA (ES:PHM) has released an update.

Pharma Mar S.A. has received a significant payment of $10 million from Janssen Products LP, a subsidiary of Johnson & Johnson, marking a commercial milestone in their license agreement for the cancer treatment drug Yondelis® in the U.S. This milestone underlines the successful collaboration between Pharma Mar and Janssen, enhancing Pharma Mar’s financial standing and reinforcing its position in the biopharmaceutical industry.

For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPharma Mar SA Reports Strong Revenue Growth in 2024
TipRanks Spain Auto-Generated NewsdeskPharma Mar S.A. Announces Strategic Share Capital Reduction
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App